| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
N10-(Trifluoroacetyl)pteroic acid targets enzymes involved in folate metabolism, such as dihydropteroate synthase. The trifluoroacetyl group is used to probe enzyme-substrate interactions within the folate pathway. The compound is a structural component of folic acid. By modifying the pteroic acid moiety, researchers can study the specificity and mechanism of folate-dependent enzymes.
|
|---|---|
| ln Vitro |
In vitro, N10-(Trifluoroacetyl)pteroic acid is used as a tool to study folate metabolism and the biosynthesis of tetrahydrofolate derivatives. The compound's trifluoroacetyl group allows researchers to probe enzyme-substrate interactions within the folate pathway. It is also used to study the transport and cellular uptake of folate compounds.
|
| ln Vivo |
In vivo, N10-(Trifluoroacetyl)pteroic acid is not administered as a therapeutic agent. It is used as a research tool to study folate metabolism and related pathways. Its incorporation into experimental models allows for the investigation of the specificity and mechanism of folate-dependent enzymes.
|
| Enzyme Assay |
In vitro enzyme assays for N10-(Trifluoroacetyl)pteroic acid involve measuring its interaction with folate-dependent enzymes such as dihydropteroate synthase. The compound's ability to inhibit or serve as a substrate for these enzymes can be assessed. Binding affinity can be measured using surface plasmon resonance or other biophysical techniques. Standard enzyme kinetic assays are used to determine inhibition constants.
|
| Cell Assay |
In vitro cellular assays for N10-(Trifluoroacetyl)pteroic acid are conducted in cell lines to study folate uptake and metabolism. Cells are treated with the compound, and its effects on folate-dependent pathways are assessed. The compound's ability to compete with natural folates for cellular uptake can be measured using radiolabeled or fluorescent folate analogs. Cellular proliferation in folate-deficient media can also be assessed.
|
| Animal Protocol |
In vivo animal studies are not typically conducted with N10-(Trifluoroacetyl)pteroic acid. The compound is used as a research tool in biochemical and cell-based assays. In vivo studies would involve administration to animal models to study folate metabolism or to evaluate folate-targeted drug delivery systems.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for N10-(Trifluoroacetyl)pteroic acid are limited. The compound is a research chemical and not a drug candidate. Its physicochemical properties, such as solubility and stability, are characterized for research applications. The compound is typically stored at room temperature.
|
| Toxicity/Toxicokinetics |
Toxicological data for N10-(Trifluoroacetyl)pteroic acid are limited. The compound is a research chemical and is not intended for human use. Standard safety precautions for handling chemical compounds apply, including the use of appropriate personal protective equipment.
|
| Additional Infomation |
N10-(Trifluoroacetyl)pteroic acid is a modified analog of pteroic acid, a key precursor in the folate pathway. It is a structural component of folic acid and can be used as a precursor to synthesize folic acid derivatives. The compound is used to study folate metabolism and the biosynthesis of tetrahydrofolate derivatives. This product is for research use only and is not intended for diagnostic or therapeutic use.
|
| Molecular Formula |
C16H11F3N6O4
|
|---|---|
| Molecular Weight |
408.29
|
| Exact Mass |
408.079
|
| CAS # |
37793-53-6
|
| PubChem CID |
135405262
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
650.2ºC at 760mmHg
|
| Melting Point |
270ºC (dec.)(lit.)
|
| Flash Point |
347.1ºC
|
| Index of Refraction |
1.698
|
| LogP |
0.3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
707
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1C(=O)O)N(CC2=CN=C3C(=N2)C(=O)NC(=N3)N)C(=O)C(F)(F)F
|
| InChi Key |
IJGIHDXKYQLIMA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H11F3N6O4/c17-16(18,19)14(29)25(9-3-1-7(2-4-9)13(27)28)6-8-5-21-11-10(22-8)12(26)24-15(20)23-11/h1-5H,6H2,(H,27,28)(H3,20,21,23,24,26)
|
| Chemical Name |
4-[(2-amino-4-oxo-3H-pteridin-6-yl)methyl-(2,2,2-trifluoroacetyl)amino]benzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4492 mL | 12.2462 mL | 24.4924 mL | |
| 5 mM | 0.4898 mL | 2.4492 mL | 4.8985 mL | |
| 10 mM | 0.2449 mL | 1.2246 mL | 2.4492 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
